Rationale for the use of radiolabelled peptides in diagnosis and therapy
- PMID: 22388630
- DOI: 10.1007/s00259-011-2038-z
Rationale for the use of radiolabelled peptides in diagnosis and therapy
Abstract
Nuclear medicine techniques are becoming more important in imaging oncological and infectious diseases. For metabolic imaging of these diseases, antibody and peptide imaging are currently used. In recent years peptide imaging has become important, therefore the rationale for the use of peptide imaging is described in this article. Criteria for a successful peptide tracer are a high target specificity, a high binding affinity, a long metabolic stability and a high target-to-background ratio. Tracer internalization is also beneficial. For oncological imaging, many tracers are available, most originating from regulatory peptides, but penetrating peptides are also being developed. Peptides for imaging inflammatory and infectious diseases include regulatory peptides, antimicrobial peptides and others. In conclusion, for the imaging of oncological, imflammatory and infectious diseases, many promising peptides are being developed. The ideal peptide probe is characterized by rapid and specific target localization and binding with a high tumour-to-background ratio.
Similar articles
-
Radiolabelling of peptides for diagnosis and therapy of non-oncological diseases.Q J Nucl Med. 2003 Dec;47(4):223-37. Q J Nucl Med. 2003. PMID: 14973415 Review.
-
Radiolabelled peptides for oncological diagnosis.Eur J Nucl Med Mol Imaging. 2012 Feb;39 Suppl 1(Suppl 1):S78-92. doi: 10.1007/s00259-011-2014-7. Eur J Nucl Med Mol Imaging. 2012. PMID: 22388627 Free PMC article. Review.
-
Radiopharmaceutical development of radiolabelled peptides.Eur J Nucl Med Mol Imaging. 2012 Feb;39 Suppl 1:S11-30. doi: 10.1007/s00259-011-2001-z. Eur J Nucl Med Mol Imaging. 2012. PMID: 22388624 Review.
-
Radiolabelled peptides in diagnosis and therapy: an introduction.Eur J Nucl Med Mol Imaging. 2012 Feb;39 Suppl 1:S1-3. doi: 10.1007/s00259-012-2064-5. Eur J Nucl Med Mol Imaging. 2012. PMID: 22388632 No abstract available.
-
Radiolabeled peptides in the diagnosis and therapy of oncological diseases.Appl Radiat Isot. 2002 Nov;57(5):749-63. doi: 10.1016/s0969-8043(02)00192-6. Appl Radiat Isot. 2002. PMID: 12433051 Review.
Cited by
-
Using 5-deoxy-5-[18F]fluororibose to glycosylate peptides for positron emission tomography.Nat Protoc. 2014 Jan;9(1):138-45. doi: 10.1038/nprot.2013.170. Epub 2013 Dec 19. Nat Protoc. 2014. PMID: 24356772
-
Advancement in treatment and diagnosis of pancreatic cancer with radiopharmaceuticals.World J Gastrointest Oncol. 2016 Feb 15;8(2):165-72. doi: 10.4251/wjgo.v8.i2.165. World J Gastrointest Oncol. 2016. PMID: 26909131 Free PMC article. Review.
-
Current Radiopharmaceuticals for Positron Emission Tomography of Brain Tumors.Brain Tumor Res Treat. 2018 Oct;6(2):47-53. doi: 10.14791/btrt.2018.6.e13. Brain Tumor Res Treat. 2018. PMID: 30381916 Free PMC article. Review.
-
Potential of Nuclear Imaging Techniques to Study the Oral Delivery of Peptides.Pharmaceutics. 2022 Dec 15;14(12):2809. doi: 10.3390/pharmaceutics14122809. Pharmaceutics. 2022. PMID: 36559303 Free PMC article. Review.
-
18F-Labeled Peptides: The Future Is Bright.Molecules. 2014 Dec 8;19(12):20536-20556. doi: 10.3390/molecules191220536. Molecules. 2014. PMID: 25493636 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources